Matches in Wikidata for { <http://www.wikidata.org/entity/Q86692459> ?p ?o ?g. }
Showing items 1 to 60 of
60
with 100 items per page.
- Q86692459 description "artículu científicu espublizáu en payares de 2013" @default.
- Q86692459 description "im November 2013 veröffentlichter wissenschaftlicher Artikel" @default.
- Q86692459 description "scientific article published on 06 November 2013" @default.
- Q86692459 description "wetenschappelijk artikel" @default.
- Q86692459 description "наукова стаття, опублікована в листопаді 2013" @default.
- Q86692459 name "Estimated GFR decline as a surrogate end point for kidney failure: a post hoc analysis from the Reduction of End Points in Non-Insulin-Dependent Diabetes With the Angiotensin II Antagonist Losartan (RENAAL) study and Irbesartan Diabetic Nephropathy" @default.
- Q86692459 name "Estimated GFR decline as a surrogate end point for kidney failure: a post hoc analysis from the Reduction of End Points in Non-Insulin-Dependent Diabetes With the Angiotensin II Antagonist Losartan (RENAAL) study and Irbesartan Diabetic Nephropathy" @default.
- Q86692459 type Item @default.
- Q86692459 label "Estimated GFR decline as a surrogate end point for kidney failure: a post hoc analysis from the Reduction of End Points in Non-Insulin-Dependent Diabetes With the Angiotensin II Antagonist Losartan (RENAAL) study and Irbesartan Diabetic Nephropathy" @default.
- Q86692459 label "Estimated GFR decline as a surrogate end point for kidney failure: a post hoc analysis from the Reduction of End Points in Non-Insulin-Dependent Diabetes With the Angiotensin II Antagonist Losartan (RENAAL) study and Irbesartan Diabetic Nephropathy" @default.
- Q86692459 prefLabel "Estimated GFR decline as a surrogate end point for kidney failure: a post hoc analysis from the Reduction of End Points in Non-Insulin-Dependent Diabetes With the Angiotensin II Antagonist Losartan (RENAAL) study and Irbesartan Diabetic Nephropathy" @default.
- Q86692459 prefLabel "Estimated GFR decline as a surrogate end point for kidney failure: a post hoc analysis from the Reduction of End Points in Non-Insulin-Dependent Diabetes With the Angiotensin II Antagonist Losartan (RENAAL) study and Irbesartan Diabetic Nephropathy" @default.
- Q86692459 P1433 Q86692459-A8CDF9EF-9D8C-48F2-B191-E798CEFEF332 @default.
- Q86692459 P1476 Q86692459-4EF2DDBC-AA93-46DE-97F1-4E1198E48293 @default.
- Q86692459 P2093 Q86692459-46E7A48E-5C1D-4F72-8002-E210CE6E9DFC @default.
- Q86692459 P2093 Q86692459-4CE9F187-F7F0-49CC-9DC1-EA94430C8A11 @default.
- Q86692459 P2093 Q86692459-51129188-4E70-4B3E-9201-39A39A1529E8 @default.
- Q86692459 P2093 Q86692459-65438860-334F-42D5-9FFF-58A49B353697 @default.
- Q86692459 P2093 Q86692459-6B3F1D44-587D-4363-B0AA-34EC05B13E0F @default.
- Q86692459 P2093 Q86692459-B076AEE4-B01E-493B-9573-8AE7CDCFB050 @default.
- Q86692459 P2093 Q86692459-E5812812-33E8-4953-BE39-76B272F091A4 @default.
- Q86692459 P2093 Q86692459-EC52A6A3-DA16-40B4-BA80-14710E28CCBF @default.
- Q86692459 P2093 Q86692459-FBE9CACF-0DA8-4B0C-9C97-B9726EE76813 @default.
- Q86692459 P304 Q86692459-7A969B28-E294-4AA4-AF07-735590544454 @default.
- Q86692459 P31 Q86692459-A80EFBE5-0CA5-4737-8586-ABD63B2357A5 @default.
- Q86692459 P356 Q86692459-A934157F-927F-49D0-A3A2-7387569AF5BF @default.
- Q86692459 P433 Q86692459-22C2448A-5D04-4683-9E2B-470618ECA560 @default.
- Q86692459 P478 Q86692459-5E741150-FC1E-4A14-86A0-6C55019A96EC @default.
- Q86692459 P50 Q86692459-28F77F94-272B-404F-8B9F-78188F2D1AEC @default.
- Q86692459 P50 Q86692459-A606717D-1F7D-429B-B556-586B86A9ACEC @default.
- Q86692459 P577 Q86692459-B9A0B27B-7331-4A31-B5B5-1B1906B31288 @default.
- Q86692459 P698 Q86692459-F1FCF782-B14D-4749-924E-8755AC5B4A01 @default.
- Q86692459 P921 Q86692459-2E62A91E-B728-4A5E-B5A0-F0CDF516AC40 @default.
- Q86692459 P921 Q86692459-915A8830-7D98-4FA5-8C4E-C8441DA90615 @default.
- Q86692459 P921 Q86692459-EB607C92-9B47-4620-88D2-4A4B3A15D146 @default.
- Q86692459 P356 J.AJKD.2013.09.016 @default.
- Q86692459 P698 24210590 @default.
- Q86692459 P1433 Q4744250 @default.
- Q86692459 P1476 "Estimated GFR decline as a surrogate end point for kidney failure: a post hoc analysis from the Reduction of End Points in Non-Insulin-Dependent Diabetes With the Angiotensin II Antagonist Losartan (RENAAL) study and Irbesartan Diabetic Nephropathy Trial (IDNT)" @default.
- Q86692459 P2093 "Andrew S Levey" @default.
- Q86692459 P2093 "Dick de Zeeuw" @default.
- Q86692459 P2093 "Hans-Henrik Parving" @default.
- Q86692459 P2093 "Hasi Mondal" @default.
- Q86692459 P2093 "Hiddo J Lambers Heerspink" @default.
- Q86692459 P2093 "Jamie P Dwyer" @default.
- Q86692459 P2093 "Lesley A Inker" @default.
- Q86692459 P2093 "Ron Gansevoort" @default.
- Q86692459 P2093 "Tom Greene" @default.
- Q86692459 P304 "244-250" @default.
- Q86692459 P31 Q13442814 @default.
- Q86692459 P356 "10.1053/J.AJKD.2013.09.016" @default.
- Q86692459 P433 "2" @default.
- Q86692459 P478 "63" @default.
- Q86692459 P50 Q30436517 @default.
- Q86692459 P50 Q58919069 @default.
- Q86692459 P577 "2013-11-06T00:00:00Z" @default.
- Q86692459 P698 "24210590" @default.
- Q86692459 P921 Q1129105 @default.
- Q86692459 P921 Q410074 @default.
- Q86692459 P921 Q476921 @default.